Latest News & Updates

Breaking News

  • 8 hours ago

  • Vaibhavi M.

EDP-978 Shows Strong Preclinical Profile As Enanta Prepares American Academy of Allergy, Asthma & Immunology(AAAAI) Presentations
Breaking News
FDA Grants Priority Review To Takeda’s Oveporexton NDA For Narcolepsy Type 1 Treatment

Vaibhavi M.

Other trending news you may like to read

EDP-978 Shows Strong Preclinical Profile As Enanta Prepares American Academy of Allergy, Asthma & Immunology(AAAAI) Presentations

Enanta to present preclinical AAAAI 2026 data showing strong potency and PK profile for EDP-978 in Type 2 inflammatory diseases.

Vaibhavi M.

Pharma Now

FDA Grants Priority Review To Takeda’s Oveporexton NDA For Narcolepsy Type 1 Treatment

FDA grants Priority Review to Takeda’s oveporexton NDA, targeting the root cause of narcolepsy type 1 via orexin signaling.

Vaibhavi M.

Pharma Now

Chugai Expands Oncology Alliance With Araris To Develop Next-Generation Antibody-Drug Conjugates

Chugai expands its oncology alliance with Araris, licensing AraLinQ technology to develop next-generation antibody-drug conjugates.

Vaibhavi M.

Pharma Now

FDA Greenlights Medicus’ Phase 2b Study Of Teverelix, A Next-Generation GnRH Antagonist For Advanced Prostate Cancer

FDA clears Medicus Pharma’s Phase 2b study of Teverelix, a long-acting GnRH antagonist for advanced prostate cancer.

Vaibhavi M.

Pharma Now